Lately, Karyopharm Therapeutics (KPTI) has been one of the top trending tickers in the healthcare industry. The stock is up by 55.65% since July 1. Ironically, the stock is down by 5.98% in 2019 YTD. Still, this has not reduced the overall interest in the stock, from investors as well as analysts.
Karyopharm Therapeutics soared on July 3, after the company announced FDA accelerated approval for the first and only nuclear export inhibitor, XPOVIO (selinexor) in combination with dexamethasone for Penta relapsed or refractory MM (multiple myeloma) patients. On the same day, the